CoChat

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation

Na, Bing, Yu, Xin, Withers, Tracy, Gilleran, John, Yao, Ming, Foo, Tzeh Keong, Chen, Chunxia, Moore, Dirk, Lin, Yong, Kimball, S. David, Xia, Bing, Ganesan, Shridar, Carpizo, Darren R. · 2019 · npj Breast Cancer
Cited by 55

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Triple negative breast cancer (TNBC) is an aggressive subset for which effective therapeutic approaches are needed. A significant proportion of TNBC patients harbor either germline or somatic mutations in BRCA1, or epigenetic silencing of BRCA1, which renders them deficient in DNA repair. Virtually all BRCA1 deficient breast cancers harbor mutations in TP53 suggesting that inactivation of p53 is a requirement for tumor progression in the setting of BRCA1 deficiency. Due to this dependency, we hypothesized that restoring wild type p53 function in BRCA1 deficient breast cancer would be therapeutic. The majority of TP53 mutations are missense, which generate a defective protein that potentially can be targeted with small molecules. Zinc metallochaperones (ZMCs) are a new class of anti-cancer drugs that specifically reactivate zinc-deficient mutant p53 by restoring zinc binding. Using ZMC1 in human breast cancer cell lines expressing the zinc deficient p53 R175H, we demonstrate that loss of BRCA1 sensitizes cells to mutant p53 reactivation. Using murine breast cancer models with Brca1 deficiency, we demonstrate that ZMC1 significantly improves survival of mice bearing tumors harboring the zinc-deficient Trp53R172H allele but not the Trp53−/− allele. We synthesized a new formulation of ZMC1 (Zn-1), in which the drug is made in complex with zinc to improve zinc delivery, and demonstrate that Zn-1 has increased efficacy. Furthermore, we show that ZMC1 plus olaparib is a highly effective combination for p53 R172H tumor growth inhibition. In conclusion, we have validated preclinically a new therapeutic approach for BRCA1 deficient breast cancer through reactivation of mutant p53.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41523-019-0110-1

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 29

  1. Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012). · DOI · Paper page
  2. Holstege, H. et al. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res. 69, 3625–3633 (2009). · DOI · Paper page
  3. Greenblatt, M. S., Chappuis, P. O., Bond, J. P., Hamel, N. & Foulkes, W. D. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res. 61, 4092–4097 (2001).
  4. Gasco, M., Yulug, I. G. & Crook, T. TP53 mutations in familial breast cancer: functional aspects. Hum. Mutat. 21, 301–306 (2003). · DOI
  5. Liu, X. et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl Acad. Sci. USA 104, 12111–12116 (2007). · DOI · Paper page
  6. Henneman, L. et al. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. Proc. Natl Acad. Sci. USA 112, 8409–8414 (2015). · DOI · Paper page
  7. Kim, Y. et al. Reverse the Resistance to PARP Inhibitors. Int. J. Biol. Sci. 13, 198–208 (2017). · DOI
  8. Jaspers, J. E. et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 3, 68–81 (2013). · DOI · Paper page
  9. Ganesan, S. Tumor suppressor tolerance: reversion mutations in BRCA1 and BRCA2 and resistance to PARP inhibitors and platinum. JCO-Precis. Oncol. 2 (2018). · DOI
  10. Schuyer, M. & Berns, E. M. Is TP53 dysfunction required for BRCA1-associated carcinogenesis. Mol. Cell. Endocrinol. 155, 143–152 (1999). · DOI
  11. Chen, Z. et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int. J. Cancer 119, 2784–2794 (2006). · DOI · Paper page
  12. Yu, X., Vazquez, A., Levine, A. J. & Carpizo, D. R. Allele-specific p53 mutant reactivation. Cancer Cell 21, 614–625 (2012). · DOI · Paper page
  13. Blanden, A. R., Yu, X., Loh, S. N., Levine, A. J. & Carpizo, D. R. Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer. Drug Discov. Today 20, 1391–1397 (2015). · DOI · Paper page
  14. Bullock, A. N. & Fersht, A. R. Rescuing the function of mutant p53. Nat. Rev. Cancer 1, 68–76 (2001). · DOI · Paper page
  15. Joerger, A. C. & Fersht, A. R. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26, 2226–2242 (2007). · DOI · Paper page
  16. Joerger, A. C., Ang, H. C. & Fersht, A. R. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc. Natl Acad. Sci. USA 103, 15056–15061 (2006). · DOI · Paper page
  17. Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev. 26, 1268–1286 (2012). · DOI · Paper page
  18. Yu, X. et al. Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget 5, 8879–8892 (2014). · DOI · Paper page
  19. Butler, J. S. & Loh, S. N. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry 42, 2396–2403 (2003). · DOI · Paper page
  20. Yu, X. et al. Thiosemicarbazones functioning as zinc metallochaperones to reactivate mutant p53. Mol Pharmacol 91, 567–575 (2017). · DOI · Paper page
  21. Blanden, A. R. et al. Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. Mol. Pharmacol. 87, 825–831 (2015). · DOI · Paper page
  22. Smith, J., Tho, L. M., Xu, N. & Gillespie, D. A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 108, 73–112 (2010). · DOI · Paper page
  23. Yu, X. et al. Zinc metallochaperones reactivate mutant p53 using an ON/OFF switch mechanism: a new paradigm in cancer therapeutics. Clin. Cancer Res. 24, 4505–4517 (2018). · DOI · Paper page
  24. Diggle, P. J, Heagerty, P., Liang, K. Y. & Zeger, S. L. Analysis of Longitudinal Data, 2nd edn. (Oxford University Press, Oxford, 2005).
  25. Wagner, K. U. et al. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res. 25, 4323–4330 (1997). · DOI · Paper page
  26. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418–425 (2001). · DOI · Paper page
  27. Harrel, F. E. Regression Modeling Strategies: With Application to Linear Models, Logistic and Ordinal Regression, and Survival Analysis, 2nd edn. (Springer Series in Statistics, Springer, Berlin, Germany, 2015). · DOI · Paper page
  28. Julious, S. A. Using confidence intervals around individual means to assess statistical significance between two means. Pharmaceutical Statistics 3, 217–222 (2004). · DOI · Paper page
  29. Cumming, G. Inference by eye: Reading the overlap of independent confidence intervals. Statistics in Medicine 28, 205–220 (2009). · DOI · Paper page

Cited by

See all 55

Metadata

Authors
Na, B., Yu, X., Withers, T., Gilleran, J., Yao, M., Foo, T. K., Chen, C., Moore, D., Lin, Y., Kimball, S. D., Xia, B., Ganesan, S., & Carpizo, D. R.
Venue
npj Breast Cancer
Published
2019-04-15
Volume
5
Issue
1
ISSN
2374-4677
Cited by
55
References
3
Language
en
Licence
Funders
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08, R01)
  • Breast Cancer Research Foundation
  • American Breast Cancer Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation. https://app.cochat.ai/papers/10.1038/s41523-019-0110-1
The paper
Na, B., Yu, X., Withers, T., Gilleran, J., Yao, M., Foo, T. K., Chen, C., Moore, D., Lin, Y., Kimball, S. D., Xia, B., Ganesan, S., & Carpizo, D. R. (2019). Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation. npj Breast Cancer. https://doi.org/10.1038/s41523-019-0110-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.